Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled TrialSammy Huygens, Jarom Heijmans, Quincy Hofsink et al.|The Journal of Infectious Diseases|2022Cited by 27
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding StudySammy Huygens, Bart Rijnders, Birgit C. P. Koch et al.|Clinical Pharmacokinetics|2024Cited by 5
SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trialSammy Huygens, Jarom Heijmans, Bart Rijnders et al.|medRxiv|2022Cited by 1
Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding studySammy Huygens, Bart Rijnders, Birgit C. P. Koch et al.|medRxiv|2023Cited by 1